GNE-274

$300$4,800

Products Details

Product Description

– GNE-274 is a non-degrader that is structurally related to GDC-0927 (ER degrader). GNE-274 does not induce ER turnover and functions as a partial ER agonist in breast cancer cell lines. GNE-274 increase chromatin accessibility at ER-DNA binding sites, while GDC-0927 do not. GNE-274 is a potent inhibitor of ER-ligand binding domain (LBD). GNE-274 can be used for cancer research[1][2].

Web ID

– HY-141551

Storage Temperature

– 4°C (Powder, protect from light, stored under nitrogen)

Shipping

– Room Temperature

Applications

– Cancer-programmed cell death

Molecular Formula

– C29H31NO4

References

– [1]Jane Guan, et al. Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility. Cell. 2019 Aug 8;178(4):949-963.e18.|[2]Jane Guan, et al. Abstract NG05: Not all “SERDs” are equal: Context-independent ER degradation and full ER antagonism define the next generation of ER therapeutics. Cancer research.

CAS Number

– 2369048-69-9

Molecular Weight

– 457.56

Compound Purity

– 98.93

SMILES

– CCCN1CC(C1)COC2=CC=C([C@@H]3OC4=CC=C(C=C4C(C)=C3C5=CC(O)=CC=C5)O)C=C2

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– DMSO : 200 mg/mL (ultrasonic)

Target

– Estrogen Receptor/ERR

Pathway

– Vitamin D Related/Nuclear Receptor

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=